<DOC>
	<DOC>NCT02300103</DOC>
	<brief_summary>This study will evaluate the efficacy, safety and tolerability of treatment with sofosbuvir (SOF)/velpatasvir (VEL; GS-5816) with ribavirin (RBV) for 24 weeks in adults with chronic hepatitis C virus (HCV) infection who participated in a prior Gilead sponsored study and did not achieve sustained virologic response (SVR).</brief_summary>
	<brief_title>Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Willing and able to provide written informed consent HCV genotype determined by the Central Laboratory HCV RNA &gt; LLOQ at screening Participated and completed a Gilead sponsored HCV treatment study of direct acting antiviral (DAA) containing regimens. Male and female of childbearing potential must agree to use protocol specified method(s) of contraception Current or prior history: Clinicallysignificant illness (other than HCV) or any other major medical disorder that may interfere with treatment, assessment or compliance with the protocol; individuals currently under evaluation for a potentially clinicallysignificant illness (other than HCV) are also excluded. Screening ECG with clinically significant abnormalities Laboratory results outside of acceptable ranges at screening Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>